Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of obinutuzumab added to standard therapy for proliferative lupus nephritis
MOH_2020-08-10_009004Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obinutuzumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (3 arms), sponsored by Roche. Primary endpoint: Primary endpoint not provided. Started Jul 2020; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2020-08-10_009004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-08-10_009004.